64Cu-肌肽-蛙皮素PET/CT在生化复发前列腺癌且68Ga-PSMA-11 PET/CT阴性或可疑患者中的效用
这项前瞻性影像研究纳入25例根治性治疗后生化复发(PSA>0.2 ng/mL)且68Ga-PSMA-11 PET/CT阴性或可疑的前列腺癌患者,行64Cu-SAR-BBN PET/CT。结果显示44%(11/25)患者发现复发灶,读者间κ评分为0.49(95%CI,0.16-0.82)。作者结论认为需进一步评估以确认诊断获益。
要点
- 64Cu-SAR-BBN PET/CT在44%(11/25)的PSMA阴性或可疑生化复发患者中检出复发灶。
- 检出部位包括局部复发12%(3/25)、盆腔淋巴结转移20%(5/25)和远处转移12%(3/25)。
- 读者间一致性κ评分为0.49(95%CI,0.16-0.82)。
核心结论
- 64Cu-SAR-BBN PET/CT在44%的68Ga-PSMA-11 PET/CT阴性或可疑的生化复发患者中显示了疾病复发部位。
- 作者认为需进一步评估以确认诊断获益。
研究设计与样本
- 前瞻性影像研究,纳入25例经确认的前列腺腺癌、既往接受过根治性治疗、生化复发(定义为PSA>0.2 ng/mL)且3个月内68Ga-PSMA-11 PET/CT阴性或可疑的男性患者。
- 64Cu-SAR-BBN PET/CT在给予200 MBq 64Cu-SAR-BBN后1小时和3小时采集,可选在24小时进行延迟显像。
- 所有PET(PSMA和蛙皮素)扫描均进行视觉评估,由2名经验丰富的核医学专家在遮蔽临床结果的情况下阅片,不一致时由第三名阅片者裁定。
- 准确性使用标准真相定义,包括活检确认、确认性影像或对靶向治疗的反应。
主要发现
- 既往根治性治疗为根治性前列腺切除术(n=24,96%)或放疗(n=1,4%)。
- 自根治性治疗的中位时间为7年(四分位距[IQR],4-11年),Gleason评分≤7分(n=15,60%)、8分(n=3,12%)或9分(n=7,28%)。
- 中位PSA为0.69 ng/mL(IQR,0.28-2.45 ng/mL)。
- 基线PSMA PET扫描阴性19例(76%),可疑6例(24%)。
- 64Cu-SAR-BBN PET阳性病变见于44%(11/25):局部复发12%(3/25),盆腔淋巴结转移20%(5/25),远处转移12%(3/25)。
关键数值与推荐
- 生化复发定义为PSA水平>0.2 ng/mL。
- 64Cu-SAR-BBN给药活度为200 MBq,显像时间点为给药后1小时和3小时,可选24小时延迟显像。
- 准确性标准真相包括活检确认、确认性影像或对靶向治疗的反应。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者结论指出需进一步评估以确认诊断获益。
- 蛙皮素PET/CT结果中44%(11/25)未验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite a high detection rate of 68Ga-prostate-specific membrane antigen (PSMA) PET/CT in biochemical recurrence (BCR) of prostate cancer, a significant proportion of men have negative 68Ga-PSMA-11 PET/CT results. Gastrin-releasing peptide receptor, targeted by the copper-chelated bombesin analog 64Cu-sarcophagine-bombesin (SAR-BBN) PET/CT, is also overexpressed in prostate cancer. In this prospective imaging study, we investigate the detection rate of 64Cu-SAR-BBN PET/CT in patients with BCR and negative or equivocal 68Ga-PSMA-11 PET/CT results. Methods: Men with confirmed adenocarcinoma of the prostate, prior definitive therapy, and BCR (defined as a prostate-specific antigen [PSA] level > 0.2 ng/mL) with negative or equivocal 68Ga-PSMA-11 PET/CT results within 3 mo were eligible for enrollment. 64Cu-SAR-BBN PET/CT scans were acquired at 1 and 3 h after administration of 200 MBq of 64Cu-SAR-BBN, with further delayed imaging undertaken optionally at 24 h. PSA (ng/mL) was determined at baseline. All PET (PSMA and bombesin) scans were assessed visually. Images were read with masking of the clinical results by 2 experienced nuclear medicine specialists, with a third reader in cases of discordance. Accuracy was defined using a standard of truth that included biopsy confirmation, confirmatory imaging, or response to targeted treatment. Results: Twenty-five patients were enrolled. Prior definitive therapy was radical prostatectomy (n = 24, 96%) or radiotherapy (n = 1, 4%). The median time since definitive therapy was 7 y (interquartile range [IQR], 4-11 y), and the Gleason score was 7 or less (n = 15, 60%), 8 (n = 3, 12%), or 9 (n = 7, 28%). The median PSA was 0.69 ng/mL (IQR, 0.28-2.45 ng/mL). Baseline PSMA PET scans were negative in 19 patients (76%) and equivocal in 6 (24%). 64Cu-SAR-BBN PET-avid disease was identified in 44% (11/25): 12% (3/25) with local recurrence, 20% (5/25) with pelvic node metastases, and 12% (3/25) with distant metastases. The κ-score between readers was 0.49 (95% CI, 0.16-0.82). Patients were followed up for a median of 10 mo (IQR, 9-12 mo). Bombesin PET/CT results were true-positive in 5 of 25 patients (20%), false-positive in 2 of 25 (8%), false-negative in 7 of 25 (28%), and unverified in 11 of 25 (44%). Conclusion: 64Cu-SAR-BBN PET/CT demonstrated sites of disease recurrence in 44% of BCR cases with negative or equivocal 68Ga-PSMA-11 PET/CT results. Further evaluation to confirm diagnostic benefit is warranted.
引用
- Li S, Nguyen A, Counter W, et al. Utility of 64Cu-Sarcophagine-Bombesin PET/CT in Men with Biochemically Recurrent Prostate Cancer and Negative or Equivocal Findings on 68Ga-PSMA-11 PET/CT. J Nucl Med. 2024. PMID: 39089814. doi:10.2967/jnumed.124.267881
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。